ArticleFrontiers in cell and developmental biology2026
Detection and prognostic role of circulating cancer-associated fibroblasts in the blood of melanoma patients.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-associated fibroblasts (CAFs), frequently present in many tumor tissues, have received increasing attention over the past decade, while research on CAFs circulating in the blood of cancer patients is still in its infancy. This is the first study to assess the incidence, concentration, and potential prognostic value of cCAFs alone or in combination with other biomarkers such as circulating tumor cells (CTCs) or cancer-associated proteins, in melanoma patients. Methods: CTCs and cCAFs were enriched from whole blood samples of 31 melanoma patients (stage IIB-IV) using the CTCeptor system, which makes use of automated density-based enrichment and CD45-based negative depletion. The isolated cells were stained with DAPI, and antibodies against MART-1, MCAM, α-SMA, and CD45. CTCs were defined as DAPI+, MART-1/MCAM+, CD45 Results: CTCs and cCAFs were detected in approximately half of the melanoma patients, respectively. On average, more cCAFs (mean: 11 cells, range: 1-60) than CTCs (mean: 4.5 cells, range: 1-20) were found in the patients' blood samples. The median progression-free survival (PFS) for patients with an increased cCAF count (≥5) was 2.07 months, while for those with a lower cCAF count (<5), it was 10.35 months (p = 0.51). When combined with elevated lactate dehydrogenase (LDH) (≥245 U/L) or S100B (≥0.152 μg/L) levels, high cCAF counts tend to a reduced PFS (high LDH/high cCAF: 1.92 months, high S100B/high cCAF: 1.77 months), compared to patients with low LDH/S100B, indicating improved risk stratification when cCAFs are used alongside established biomarkers. Conclusion: This study demonstrates the possibility of co-detecting CTCs and cCAFs in the blood of melanoma patients for the first time. A higher mean number of cCAFs was detected and showed a trend toward shorter progression-free survival. The encouraging results of this pilot study need to be validated on a larger cohort of melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.